Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd (NQ: TLSA )

0.9249 -0.0034 (-0.37%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,551
Open 0.9400
Bid (Size) 0.9000 (44)
Ask (Size) 0.9500 (1)
Prev. Close 0.9283
Today's Range 0.9000 - 0.9499
52wk Range 0.4100 - 1.740
Shares Outstanding 194,612,289
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tiziana Life Sciences Appoints New Chief Executive Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Performance

YTD
+62.23%
+62.23%
1 Month
-15.15%
-15.15%
3 Month
+24.99%
+24.99%
6 Month
+85.09%
+85.09%
1 Year
+30.18%
+30.18%

More News

Read More
The 3 Best EV Stocks to Buy in August 2024
Via InvestorPlace
Tiziana Life Sciences Granted FDA Fast Track Designation
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Receives $3.4 Million in Non-Dilutive Funding
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences adds to treasury with $3.4 million in non-dilutive funding
Via News Direct
Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
Via FinancialNewsMedia
Exposures Product Safety
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
EXCLUSIVE: Top Tesla Options Trades Recommended By Trading Expert
Via Benzinga
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.